Pharmacokinetic and Safety Study of Nab®-Paclitaxel (ABI-007) Plus Gemcitabine in Subjects With Advanced Pancreatic Cancer Who Have Cholestatic Hyperbilirubinemia
Clinical trial NCT02267707 · TERMINATED
Trial details
- NCT number
- NCT02267707
- Sponsor
- Celgene
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2015-05-27
- Primary completion
- 2016-02-10
- Enrollment
- 1
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.